Literature DB >> 8368644

Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa?

S Sur1, T B Crotty, G M Kephart, B A Hyma, T V Colby, C E Reed, L W Hunt, G J Gleich.   

Abstract

To determine the histologic differences in the airways of patients who died from sudden-onset asthma and the more common slow-onset asthma, we studied seven cases of fatal asthma. The numbers of eosinophils and neutrophils, as well as extracellular deposition of their respective granule contents in the airway mucosa and submucosa, were determined and statistically analyzed. Four of the seven patients had slow-onset asthma attacks in which the time interval between onset of asthma and death was more than 2.5 h. In contrast, three patients had sudden-onset asthma in which the time interval between onset of asthma attack and death was less than 1 h. The four patients with slow-onset fatal asthma had more eosinophils (34.1 +/- 6.3 in slow-onset; 9.7 +/- 3.5 in sudden-onset; p = 0.002) and fewer neutrophils (4.8 +/- 2.0 in slow-onset; 16.8 +/- 5.4 in sudden-onset; p = 0.008) in the airway submucosa than did patients with sudden-onset fatal asthma. In addition, within the slow-onset fatal asthma group, eosinophils exceeded neutrophils in the airway submucosa (eosinophils > neutrophils, p = 0.002). By contrast, within the sudden-onset fatal asthma group, neutrophils exceeded eosinophils (neutrophils > eosinophils, p = 0.04). We suggest that sudden-onset fatal asthma is immunohistologically distinct from slow-onset fatal asthma and that it is characterized by a relative paucity of eosinophils in the face of an excess of neutrophils in the airway submucosa.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8368644     DOI: 10.1164/ajrccm/148.3.713

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  101 in total

Review 1.  Severe acute asthma.

Authors:  S Salmeron; M Bard; F X Blanc; A Ellrodt
Journal:  Clin Rev Allergy Immunol       Date:  1999       Impact factor: 8.667

Review 2.  Airway hyperresponsiveness in asthma: not just a matter of airway inflammation.

Authors:  V Brusasco; E Crimi; R Pellegrino
Journal:  Thorax       Date:  1998-11       Impact factor: 9.139

Review 3.  Pathophysiological mechanisms of asthma. Application of cell and molecular biology techniques.

Authors:  K F Chung; I M Adcock
Journal:  Mol Biotechnol       Date:  2001-07       Impact factor: 2.695

Review 4.  Status asthmaticus. From the emergency department to the intensive care unit.

Authors:  N Kenyon; T E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2001-06       Impact factor: 8.667

Review 5.  Low dose inhaled corticosteroids and the prevention of death from asthma.

Authors:  J C Kips; R A Pauwels
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

Review 6.  Management of severe asthma in children.

Authors:  Andrew Bush; Sejal Saglani
Journal:  Lancet       Date:  2010-09-04       Impact factor: 79.321

7.  Strategies for molecular classification of asthma using bipartite network analysis of cytokine expression.

Authors:  Regina R Pillai; Rohit Divekar; Allan Brasier; Suresh Bhavnani; William J Calhoun
Journal:  Curr Allergy Asthma Rep       Date:  2012-10       Impact factor: 4.806

Review 8.  Similarities and discrepancies between exacerbations of asthma and chronic obstructive pulmonary disease.

Authors:  L Fabbri; B Beghé; G Caramori; A Papi; M Saetta
Journal:  Thorax       Date:  1998-09       Impact factor: 9.139

Review 9.  Neutrophils in asthma.

Authors:  Ana L Macdowell; Stephen P Peters
Journal:  Curr Allergy Asthma Rep       Date:  2007-11       Impact factor: 4.806

10.  ROS generated by pollen NADPH oxidase provide a signal that augments antigen-induced allergic airway inflammation.

Authors:  Istvan Boldogh; Attila Bacsi; Barun K Choudhury; Nilesh Dharajiya; Rafeul Alam; Tapas K Hazra; Sankar Mitra; Randall M Goldblum; Sanjiv Sur
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.